Your session is about to expire
What is Vidaza
AzacitidineThe Generic name of this drug
Treatment SummaryAzacytidine is a type of drug used to treat cancer. It works by inhibiting an enzyme called DNA methyltransferase, which helps to prevent the growth of tumors. It also works by blocking the production of RNA, which is essential for cell growth. Azacytidine has been used as an anti-cancer drug for many years.
Vidazais the brand name
Vidaza Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Vidaza
Azacitidine
2004
34
Approved as Treatment by the FDA
Azacitidine, commonly known as Vidaza, is approved by the FDA for 3 uses like Acute Myeloid Leukemia and multilineage dysplasia .Acute Myeloid Leukemia
multilineage dysplasia
20-30% blasts
Effectiveness
How Vidaza Affects PatientsAzacitidine is thought to work against cancer by changing the way DNA is made and by killing abnormal cells in the bone marrow. It does this by affecting the way cells use and make DNA. Azacitidine is most effective when cells are rapidly dividing, as normal cells that aren't dividing don't react to it. Once inside cells, it is changed into other forms which disrupt the way the cell makes RNA and proteins, as well as DNA. Azacitidine is most effective when cells are in the S-phase of the cell cycle.
How Vidaza works in the bodyAzacitidine is a medication that works by preventing the growth of cancer cells. It does this by blocking the activity of DNA methyltransferase, which stops the cells from reproducing. It also has a toxic effect on the cells, causing them to die. Azacitidine is incorporated into DNA and RNA, which disrupts the cells' ability to produce proteins, which leads to their death.
When to interrupt dosage
The measure of Vidaza is contingent upon the determined condition, including induction chemotherapy, 20-30% blasts and Anemia. The measure of dosage shifts as indicated by the strategy of delivery (e.g. Subcutaneous or Tablet - Oral) specified in the chart below.Condition
Dosage
Administration
Anemia
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
20-30% blasts
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
induction chemotherapy
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
Acute Myeloid Leukemia
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
multilineage dysplasia
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
Chronic Myelomonocytic Leukemia
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
Complete Remission
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
Anemia, Refractory
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
Anemia
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
Blood Transfusion
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
Malignant Neoplasms
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
neutropenia and/or thrombocytopenia
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
Complete Blood Count
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
Anemia
100.0 mg, , 10.0 mg/mL, 100.0 mg/mL, 1.0 mg/mg, 200.0 mg, 25.0 mg/mL, 300.0 mg
Powder, for suspension, , Powder, for suspension - Subcutaneous, Subcutaneous, Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution - Subcutaneous, Injection, powder, lyophilized, for suspension - Subcutaneous, Injection, powder, lyophilized, for suspension, Tablet, film coated, Tablet, film coated - Oral, Oral, Tablet, Tablet - Oral
Warnings
Vidaza has two prohibitions and should not be taken when you are dealing with any of the conditions given in the following table.Vidaza ContraindicationsCondition
Risk Level
Notes
Liver Neoplasms
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Azacitidine may interact with Pulse Frequency
Common Vidaza Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Azacitidine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Azacitidine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Azacitidine is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Azacitidine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Azacitidine is combined with Acteoside.
Vidaza Toxicity & Overdose RiskA patient who overdosed on azacitidine reported experiencing diarrhea, nausea, and vomiting. The patient had received a single IV dose of nearly 4 times the recommended starting dose (290 mg/m2).
Vidaza Novel Uses: Which Conditions Have a Clinical Trial Featuring Vidaza?
Currently, 367 active studies are examining the potential benefits of Vidaza for treating Chronic Myelomonocytic Leukemia, Blood Transfusion and Multilineage Dysplasia.Condition
Clinical Trials
Trial Phases
Anemia, Refractory
0 Actively Recruiting
Complete Remission
0 Actively Recruiting
Chronic Myelomonocytic Leukemia
50 Actively Recruiting
Phase 1, Phase 3, Phase 2, Early Phase 1
Blood Transfusion
0 Actively Recruiting
Acute Myeloid Leukemia
276 Actively Recruiting
Phase 2, Phase 1, Phase 3, Phase 4, Not Applicable, Early Phase 1
induction chemotherapy
0 Actively Recruiting
Complete Blood Count
0 Actively Recruiting
Anemia
0 Actively Recruiting
Anemia
0 Actively Recruiting
neutropenia and/or thrombocytopenia
0 Actively Recruiting
20-30% blasts
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Anemia
0 Actively Recruiting
multilineage dysplasia
0 Actively Recruiting
Vidaza Reviews: What are patients saying about Vidaza?
5Patient Review
11/16/2012 I'm on my 28-day cycle of infusions with Vidaza and things are going great so far. I see vast improvement from when I started and the side effects haven't been too bad.
5Patient Review
9/18/2013 I was able to go without transfusions for 2.5 years while on this drug, which is amazing. I only wish it had worked longer for me. The mild constipation I experienced was my only issue.
5Patient Review
3/6/2019 I've been on Vidaza for over two years now and it's been a life-saver. I'm approaching 250 injections in total, with no negative side effects that I can tell. Blood tests have also been regular, but again – no problems there, either.
4.3Patient Review
1/22/2010 I've been noticing more cramping and weight gain since I started taking Vidaza.
4.3Patient Review
1/2/2011 I'm on my fourteenth cycle of this treatment, which includes five days of consecutive hip injections (200 mg.) daily, followed by a four week break. I was diagnosed with MDS in 1998 and have had approximately 50 units of red packed cells since then. This treatment has allowed me to be transfusion independent for the past twelve months.
3.7Patient Review
1/5/2012 I had really bad constipation and muscle/joint pain before starting this treatment, but even after only seven sessions, the side effects weren't worth it for me.
3.7Patient Review
9/11/2011 I've been on this treatment for 4 cycles now. I used to need a blood or platelet transfusion every single week, but now I haven't needed one in 2 months. My white blood cells have decreased somewhat, but my doctor is still pleased with the overall results. The worst side effects for me are soreness and redness at the injection site, blistering, and constipation.
3.3Patient Review
5/4/2010 I didn't notice any difference.
3.3Patient Review
1/18/2013 I'm currently on my third cycle of this treatment, and I've experienced some mild constipation. My diagnosis is MDS, and since being diagnosed 3/12, I've constantly dealt with hives and skin rash.
3.3Patient Review
8/4/2015 My blood counts were low when I started this treatment, and after the first dose of the first cycle I felt nauseous. So far the drug hasn't helped me, but I'm hoping it will start working soon.
3Patient Review
5/16/20092.3Patient Review
3/31/2010 I had seven injections of Vidaza and, surprisingly, I experienced a burst of energy that lasted for hours afterwards with no negative side-effects.
2Patient Review
5/9/2014 I only felt slightly nauseous after taking this medication.
1.7Patient Review
4/2/2014 This drug caused me to develop eosophilic pneumonia, which after only two treatments of Vidaza, almost killed me. It took a huge team of doctors (pulmonologists, cardiologoists and the whole hematologists) to bring me back to some semblance of normalcy. They took me off all MDS meds for three years. I've been okay for three years but now because blood levels have dropped due to a virus, they are wanting me to try another drug. Naturally I am very wary.
1.7Patient Review
3/17/2017 While this medication was still in clinical trials, I was given the opportunity to try it. Unfortunately, after just one cycle my bone marrow function decreased from 50% to 20%. I had to be removed from the trial and underwent a stem cell transplant. Thankfully, that was successful and I've been in remission for seven years now.
Patient Q&A Section about vidaza
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is the success rate of Vidaza?
"Vidaza has been shown to help 40% of patients with TP53-mutated myelodysplastic syndromes and acute myeloid leukemia, 20% of whom achieve complete remission. However, the duration of the response is relatively short, and the overall survival rate is six months."
Answered by AI
Is Vidaza considered chemo?
"Azacitadine is the generic name for the cancer drugs Vidaza or Onureg. Sometimes, health care professionals will use the trade name or the generic name when referring to the drug."
Answered by AI
How long can you stay on Vidaza?
"We recommend that patients be treated with azacitidine for at least 6 months, and that in patients who achieve a documented response or stable disease (sd), treatment be continued until disease progression or unacceptable toxicity occurs."
Answered by AI
What is the drug Vidaza used for?
"Azacitidine is a cancer treatment, also called by its brand name, Vidaza. It is a treatment for people who can't have high dose treatment with a stem cell transplant for chronic myelomonocytic leukaemia (CMML) or acute myeloid leukaemia (AML)."
Answered by AI